Study of GO-203-2C Given Intravenously in Patients With Advanced Solid Tumors Including Lymphomas
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
This clinical trial is about testing GO-203-2c, which is a newly discovered compound that
binds to an oncoprotein (a cancer causing protein) called MUC1 (which is over-expressed in
many cancers). By binding to MUC1, GO-203-2c eventually causes tumor cell death in laboratory
studies.
This study is being done to:
- Test the safety of GO-203-2c and see what effects (good and bad) it has on you and your
cancer
- Find the highest dose of GO-203-2c that can be given without causing bad side effects
- Examine how much GO-203-2c is in the blood at certain times after it is given and how
quickly the body gets rid of it
- Observe whether there is any effect of GO-203-2c on the size and activity of cancer in
your body